Skip to main content
. 2020 Nov 5;10:19227. doi: 10.1038/s41598-020-76222-y

Table 2.

Biomarkers of exposure levels at baseline and Day 5.

Biomarker CHTP (n = 41)
Estimate (95% CI)
Cigarettes (n = 39)
Estimate (95% CI)
COHb (%)
Baseline 5.8 (5.3; 6.3) 5.6 (5.1; 6.2)
Day 5 2.7 (2.2; 3.2) 6.4 (5.7; 7.1)
% change  − 50.4 (− 58.8; − 41.9) 7.6 (− 0.1; 15.2)
MHBMA (pg/mg creatinine)
Baseline 1635.31 (1245.24; 2147.55) 1466.37 (1048.61; 2050.56)
Day 5 339.73 (301.82; 382.42) 1840.61 (1275.38; 2656.32)
% change  − 72.6 (− 80.0; − 65.3) 32.2 (18.5; 45.9)
3-HPMA (ng/mg creatinine)
Baseline 1086.68 (928.83; 1271.35) 947.83 (817.32; 1099.18)
Day 5 494.70 (417.53; 586.12) 1187.97 (1026.63; 1374.65)
% change  − 53.0 (− 56.9; − 49.2) 28.1 (19.6; 36.6)
S-PMA (pg/mg creatinine)
Baseline 2432.70 (1919.90; 3082.47) 2301.95 (1732.67; 3058.27)
Day 5 361.48 (289.26; 451.74) 2898.46 (2172.62; 3866.79)
% change  − 84.2 (− 85.9; − 82.6) 28.9 (19.9; 37.8)
Total 1-OHP (pg/mg creatinine)
Baseline 242.85 (210.44; 280.25) 194.25 (166.36; 226.82)
Day 5 106.33 (93.18; 121.33) 199.12 (171.73; 230.88)
% change  − 55.3 (− 58.3; − 52.2) 4.7 (− 2.5; 12.0)
4-ABP (pg/mg creatinine)
Baseline 16.76 (14.50; 19.37) 14.56 (12.61; 16.82)
Day 5 3.71 (3.28; 4.18) 15.91 (13.79; 18.34)
% change  − 76.5 (− 79.2; − 73.8) 11.0 (4.5; 17. 6)
1-NA (pg/mg creatinine)
Baseline 93.14 (81.79; 106.06) 90.67 (78.32; 104.96)
Day 5 3.44 (2.82; 4.20) 115.76 (100.49; 133.35)
% change  − 95.8 (− 96.5; − 95.0) 30.3 (21.9; 38.6)
2-NA (pg/mg creatinine)
Baseline 27.45 (24.11; 31.26) 25.07 (21.53; 29.20)
Day 5 3.15 (2.70; 3.69) 29.37 (25.36; 34.02)
% change  − 87.7 (− 89.1; − 86.4) 18.8 (12.3; 25.4)
o-tol (pg/mg creatinine)
Baseline 152.30 (137.11; 169.16) 149.95 (126.73; 177.42)
Day 5 49.26 (43.59; 55.67) 175.40 (156.97; 195.99)
% change  − 65.5 (− 69.8; − 61.2) 24.4 (9.3; 39.4)
CEMA (ng/mg creatinine)
Baseline 130.08 (107.27; 157.74) 126.88 (107.86; 149.25)
Day 5 20.78 (16.66; 25.92) 143.18 (122.59; 167.22)
% change  − 83.3 (− 84.9; − 81.7) 15.3 (7.7; 22.8)
HEMA (pg/mg creatinine)
Baseline 3123.34 (2305.75; 4230.81) 2876.32 (2307.89; 3584.76)
Day 5 1146.84 (913.06; 1440.48) 3094.70 (2477.69; 3865.35)
% change  − 58.3 (− 66.1; − 50.6) 11.8 (1.6; 22.1)
HMPMA (ng/mg creatinine)
Baseline 481.38 (428.98; 540.17) 451.09 (394.98; 515.17)
Day 5 125.75 (110.46; 143.16) 484.18 (420.56; 557.41)
% change  − 72.9 (− 75.2; − 70.6) 10.1 (1.9; 18.4)
Total NNAL (pg/mg creatinine)
Baseline 162.41 (129.89; 203.06) 106.86 (83.69; 136.43)
Day 5 74.70 (59.90; 93.17) 117.82 (91.61; 151.53)
% change  − 52.7 (− 56.3; − 49.1) 12.5 (5.1; 19.9)
3-OH-B[a]P (fg/mg creatinine)
Baseline 145.72 (119.17; 178.19) 107.10 (87.22; 131.50)
Day 5 33.23 (27.37; 40.35) 116.77 (95.09; 143.40)
% change  − 72.4 (− 79.9; − 65.0) 12.5 (3.3; 21.7)
Total NNN (pg/mg creatinine)
Baseline 7.04 (5.19; 9.56) 4.99 (3.91; 6.36)
Day 5 2.13 (1.73; 2.63) 6.12 (4.87; 7.70)
% change  − 59.2 (− 68.6; − 49.8) 28.6 (16.3; 40. 8)

Biomarkers of exposure from 24-h urine creatinine-adjusted samples (COHb measured in blood). Baseline and Day 5 values presented as geometric mean (95% CI). % change refers to mean percent change from baseline to Day 5. Acronyms of biomarkers are provided in Supplementary Table 1.

CHTP Carbon-Heated Tobacco Product 1.0., CI confidence interval.